Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...

Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.

Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

Aging and shifting hormone levels influence how MS changes over time, and the overlap of these factors during midlife can ...

A wearable system that measures the brain's electrical activity can show how brain circuits are affected in people with MS, a ...

The longtime weather anchor, 55, who was diagnosed with multiple sclerosis in 2005, said she’ll also be taking a break from ...